CRBU

Caribou Biosciences, Inc.

• Reuters·1d ago

  Caribou Biosciences announces annual shareholder meeting notice

• Dow Jones·4d ago

  Caribou Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

• Benzinga·4d ago

  HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target

• TipRanks·4d ago

  Analysts Offer Insights on Healthcare Companies: Adagene (ADAG), Caribou Biosciences (CRBU) and Praxis Precision Medicines (PRAX)

• NASDAQ·04/02 13:03

  Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?

• Reuters·03/31 21:43

  Caribou says FDA grants RMAT designation for CB-011 multiple myeloma CAR-T therapy

• Reuters·03/31 21:21

  Caribou says FDA grants RMAT designation to CB-011 allogeneic BCMA CAR-T therapy

• Reuters·03/31 16:19

  BUZZ-U.S. STOCKS ON THE MOVE -Shake Shack, Perpetua, Caribou Biosciences

• TipRanks·03/31 15:10

  Caribou Biosciences Gains RMAT Status for CB-011 Therapy

• Reuters·03/31 13:08

  BUZZ-U.S. STOCKS ON THE MOVE-Stryker, TD Synnex, Factset

• Seeking Alpha·03/31 12:43

  Caribou rises on FDA RMAT designation for CAR-T therapy

• Reuters·03/31 12:22

  BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy

• TipRanks·03/31 12:21

  Caribou CB-011 granted Regenerative Medicine Advanced Therapy designation

• Benzinga·03/31 12:02

  Caribou Biosciences Receives FDA's Regenerative Medicine Advanced Therapy Designation To CB-011 For Relapsed Or Refractory Multiple Myeloma

• Reuters·03/31 12:01

  CARIBOU BIOSCIENCES ANNOUNCES THE FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION TO CB-011, AN ALLOGENEIC ANTI-BCMA CAR-T CELL THERAPY